The Vaccines and Related Biological Products Advisory Committee of the FDA discussed the safety concerns surrounding the development of an RSV vaccine for infants, particularly mRNA vaccines produced by Moderna. While RSV is a serious respiratory disease in infants, potential side effects of the vaccine have led Moderna to halt their study for children aged 5-8 months due to concerns about severe side effects. The committee agreed that more data is needed to understand the safety and effectiveness of the vaccine, especially in younger children. Additional research on vaccine-enhanced disease and immune responses is crucial before proceeding with RSV vaccine development for infants.
Source link
RSV Vaccine Research in Infants May Proceed With Caution
